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Abstract
Background: Behçet’s disease is a rare multi-systemic inflammatory disease with unknown etiology which involves
principally oral and genital mucosa, skin and eyes. Average age at onset of the disease is about 25-30 years, but it
may be diagnosed before the age of 16. It is not very rare in Italy, even though there are limited data concerning
epidemiology. Aim of this study is to describe the baseline data of an Italian cohort of patients with as having BD
or probable BD.
Methods: We described the baseline data of the first national epidemiological study on children coming from 16
Italian Pediatric Rheumatologic Centers diagnosed by the treating physicians as having Behçet’s Disease. Data on
demographic characteristics, clinical features and therapy were collected. We then compared our findings to those
of international pediatric cohort studies and also retrospectively evaluated the ability to diagnose BD using ISG,
ICBD and, for the first time, the new PEDBD criteria.
Results: The study included 110 patients (62 M, 48F). Average age at onset was 8.34±4.11 years. The frequencies of
signs/symptoms were: recurrent oral aphtosis 94.5%, genital ulcers 33.6%, ocular 43.6%, gastrointestinal 42.7%,
musculoskeletal 42.7%, neurological 30.9% and vascular involvement 10%. Thirty-two patients (29.1%) fulfilled ISG,
78 (70.9%) ICBD, 50 (45.5%) PEDBD criteria and 31 (28%) didn’t fulfill any of them. The most frequently used
treatments were colchicine and corticosteroids followed by immunosuppressants. Four patients received biologic
therapy (anti TNF-α and anti-IL-1) to treat severe organ involvement.
Conclusions: Recurrent oral aphtosis was the most frequent clinical manifestation, followed by ocular involvement.
Gastrointestinal lesions were more frequent in Italy than in non-European countries as opposed to genital ulcers.
Skin, ocular and vascular manifestations had a higher frequency in males and genital ulcers in females.
Constitutional symptoms were present in 44.5% and recurrent fever in one third of our population.
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Background
Behçet’s disease (BD) is defined as a multi-systemic
inflammatory disease with unknown etiology and chronic
recurrent pattern, characterized by oral and genital
aphthous ulcerations, ocular, skin, articular, vascular,
gastrointestinal and central nervous system lesions. BD is
included both in vasculitis and autoinflammatory diseases
classifications [1]. It is considered a vasculitis affecting
vessels of all sizes and defined as a multifactorial autoin-
flammatory syndrome [2, 3]. Average age at onset of the
disease is about 25-30 years, but it may be diagnosed in
children before the age of 16 in about 4-26% of cases. Sex
distribution is roughly equal, with a worse clinical course
in men [4]. BD is prevalent in “Silk Road” populations
from East (China) to West (Spain and Portugal): 100/
100.000 in China and Iran and 80-370/100.000 in Turkey
[5]. Disease occurrence is far lower in European countries
such as France, Germany, Sweden, and Italy [6, 7]. Epi-
demiological studies show a higher prevalence among the
southern Italian population compared to the north of
Italy: 15.9/100.000 in Potenza (Southern Italy) and 3.80/
100.000 in Reggio Emilia (Northern Italy) [6, 8], probably
because the south of Italy is part of the “Silk Road”.
Etiology is still unknown; pathogenetic mechanisms
involve interactions between genetic and environmental
factors. The association with human leukocyte antigen
(HLA)-B51 is known as the strongest associated genetic
risk factor. Furthermore, it has recently been discovered
that the haploinsufficiency of A20 protein is related to a
“Behçet-like” phenotype with autosomal dominant inherit-
ance [9]. T-lymphocytes play a role, in particular those
secreting Interleukin (IL)-17 and IL-21, mostly in acute at-
tacks of BD [7]. There are no pathognomonic tests nor
biomarkers to make the diagnosis, which is based on clin-
ical criteria. The most current criteria used are those
developed by an international study in 1990 called the
International Behçet’s Study Group (ISG) [10] with 85%
sensitivity and 96% specificity. Recently, International
Criteria for Behçet’s Disease (ICBD) [11] have been
validated in adults, with 94.8% sensitivity and 90.5% speci-
ficity. Considering these results, the latter should be used
as the gold standard. Neither of them has been validated
in children. Recently, an international expert consensus
group, the Pediatric BD group (PEDBD) has proposed a
new set of criteria for the diagnosis of Behçet’s Disease in
children. This new international PEDBD criteria has
higher sensitivity (91.7%), but lower specificity (42.9%)
when compared to ISG [12, 13]. Treatments include top-
ical and systemic corticosteroids, colchicine, immunosup-
pressants and biological therapy. The therapeutic choice
and prognosis depend on clinical involvement. Loss of
visual acuity and neurological disease are major causes of
morbidity and disability. The primary aim of this study
was to collect information on demographic, clinical and
therapeutic data from pediatric patients with BD enrolled
in the Eurofever registry by Italian Pediatric Rheumatology
Centers and to compare these data with other inter-
national pediatric studies. A secondary aim was to explore
the ability to diagnose BD through the ISG, ICBD and
PEDBD criteria in this pediatric cohort. In this study we
report the baseline data of a cohort of Italian patients with
BD or probable BD enrolled in a longitudinal registry.
Methods
All patients came from sixteen Italian Pediatric Rheuma-
tologic Centers of fourteen cities (Fig. 1) and the data
analyzed in our study were extracted from the Eurofever
registry, collected through a secured registry on a https
platform hosted in the Paediatric Rheumatology INter-
national Trials Organization (PRINTO) Website
(https://www.printo.it/). Ethical committee approval for
entering patients in the registry and informed consent
were obtained in the participating centers as per local
regulations. We included consecutive pediatric patients
affected by BD who met ISG or were diagnosed by phys-
ician as being affected by BD or probable BD. Disease
onset after the age of 16 was considered a reason for
exclusion. Patients were diagnosed and entered in the
registry by their local physician. In case of inconsistency
or other doubts, specific queries were resubmitted to the
participating centers for resolution. Data extracted
included the following information: demographics (sex,
age at onset, age at diagnosis), ethnicity, family history,
clinical manifestations (mucocutaneous, musculoskeletal,
ocular, gastrointestinal, vascular, neurological manifesta-
tions), the presence of HLA B51 and treatment. We
tested the applicability of ISG, ICBD and PEDBD criteria
in our cohort.
Statistical analysis
All quantitative and qualitative variables are reported as
mean and standard deviation. Assumption of normal
distribution for continuous variables was tested by
Shapiro-Wilk test. Non-normally distributed variables
were compared by Mann-Whitney U test. The Chi-
square test was utilized to assess the association between
clinical manifestations (mucocutaneous, ocular, gastro-
intestinal, vascular, neurological involvement) and
gender and also HLA B51. A p value <0.05 was consid-
ered statistically significant. All the processing was done
using the R software (https://www.r-project.org/). The
frequency of patients who met ISG, ICBD and PEDBD
criteria was evaluated.
Results
One hundred and ten patients were included in our
study, 62 males and 48 females, coming from 16 Italian
Pediatric Rheumatologic Centers of 14 cities. There were
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familial cases in 12% of our patients. Average age at
onset was 8.34 ± 4.11 years and average age at diagnosis
11.29 ± 3.95 years. All patients were Caucasians.
Clinical features
Mucocutaneous symptoms were present in 106/110
patients (96.4%), isolated skin lesions in 36 (39.6%); ocu-
lar involvement in 48 (43.6%), gastrointestinal (GI) in 47
(42.7%); musculoskeletal in 47 (42.7%); neurological in
34 (30.9%), vascular in 2 (1.8%) and constitutional symp-
toms in 49 (44.5%). Among mucocutaneous manifesta-
tions, the most common was recurrent oral aphtosis
(ROA) in 104 (94.5%) followed by genital ulcers (GU) in
37 (33.6%), pseudo-follicolitis in 16 (14.5), erythema
nodosum in 15 (13.6%), papulo-pustular lesions in 13
(11.8%) and acneic lesions in 12 (10.9%). Pathergy test
was positive in 14.5% of cases in which it was performed
(15/103). Ocular involvement occurred in 48 patients: 27
(24.5%) as anterior uveitis, 14 (12.7%) posterior uveitis, 9
(8.2%) retinal vasculitis, 7 (6.4%) papilledema, 5 (4.5%)
papillitis, 4 (3.6%) episcleritis and 2 keratitis (1.8%).
Arthralgia was present in 45 cases (41%) and arthritis in
25 (22.7%): (14 oligoarthritis, 8 polyarthritis and 3
monoarthritis). Abdominal pain in 45 (41%) and
diarrhea in 15 (13.6%) were the most common GI symp-
toms, 7 (6.4%) had GI bleeding, 5 (4.5%) GI ulcers, 5
(4.5%) anal ulcers and 2 (1.8%) gut perforation. Head-
ache was the main neurologic symptom, being present
in 27 cases (24.5%), while 5 (4.5%) showed cranial nerve
palsy, 2 (1.8%) cranial neuropathy, 2 (1.8%) aseptic men-
ingitis, 2 (1.8%) optic neuritis, 1 (0.9%) peripheral neur-
opathy. Venous thrombosis occurred in 2 patients, with
thrombosis of transverse sinus in one of them. Constitu-
tional symptoms included recurrent fever in 34 (30.9%),
malaise in 32 (29.1%), fatigue in 31 (28.1%) and mood
disorder in 7 (6.4%) patients (Fig. 2). Twenty-nine
(26.3%) patients had a continuous disease course, 67
(60.9%) recurrent and 14 (12.72%) continuous-recurrent.
Laboratory findings
HLA-B51 testing was performed in 88 patients and was
present in 50 (56.8%). More than half of our patients
Fig. 1 Italian Pediatric Rheumatologic Centers
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(54.5%) had increased acute phase reactants (erythrocyte
sedimentation rate and C-reactive Protein). Genetic test-
ing for autoinflammatory conditions was performed in
16/110 patients (16/34 with recurrent fever): Familial
Mediterranean Fever (FMF) 16/16; Tumor Necrosis Fac-
tor Receptor Associated Periodic Syndrome (TRAPS)
13/16 and Mevalonate Kinase Deficiency (MVK) 5/16.
Results were negative in all cases.
Treatment
All patients received topical steroid therapy (ocular and/
or mucocutaneous). The most used systemic treatments
were colchicine in 33 patients (30%), as monotherapy in
22 and in combination in 11 and corticosteroids in 33
(30%) patients (as monotherapy in 14); immunosuppres-
sants in 13 (11.8%) with the following drugs: 7 Metho-
trexate, 6 Azathioprine, 6 Cyclosporine, 2 Thalidomide,
1 Cyclophosphamide, 1 Sulphasalazine. Anti-tumor ne-
crosis factor-alpha (anti TNF-α) was used in 2 patients
(Infliximab) and anti-IL-1 (Anakinra) in 2. Non Steroidal
Anti-Inflammatory Drugs (NSAIDs) were used in 4
cases.
Diagnostic criteria
Out of the 110 patients, 32 (29.1%) met the ISG, 78
(70.9%) ICBD and 50 (45.5%) PEDBD criteria; 28 (25.5%)
met all three, 25 (22.7%) two criteria and 31 (28%) did
not meet any of them.
Discussion
We described the baseline data of the first national
epidemiological study on BD in Italian children and
compared our findings to those of other international
pediatric cohort studies (Table 1). In the literature, there
are few epidemiological data on pediatric BD, mostly
limited to case reports or case series. In our patients the
average age of disease onset was 8.3 ± 4.1 years, similar
to most of the studies we analyzed. This age was
however earlier in the English population (4.8 years) [14]
and later in life in Tunisia (16.1 years) [15], while the
average age of diagnosis was 11.2 ± 3.9 years. To date,
the main problem remains diagnosis, as BD is character-
ized by remittance and exacerbations and the symptoms
are separated from one another by years, which can
result in delay of diagnosis up to 13.5 years [14]. In our
study, we noted a diagnostic delay of only 3 years (2.9 ±
3.6), probably since our patients came from pediatric
rheumatologic centers of high expertise. In children,
even though the first symptoms may start very early, the
disease is rarely complete before the age of 16 [15] and,
because of a lack of awareness of BD, other better
known pathologies are more often hypothesized (e.g.
immunodeficiency, gastrointestinal diseases).
The sex ratio was not consistent among the studies
analyzed. Familial cases can occur, with figures ranging
widely from 12% in our study to 42% in Turkey [16].
According to Koné-Paut et al. the frequency of familial
cases is significantly higher (p < 0.0001) in pediatric BD
patients (12.3%) than in non-pediatric patients (2.2%)
and this suggests a strong genetic component [17]. A
genetic influence on disease predisposition is also sup-
ported by the recent discovery of a familial form (A20
gene), which has the clinical manifestations of BD in
multiple family members.
ROA is by far the most frequent clinical manifestation,
with a lower rate in our population than in all the other
studies. Ocular involvement is the second manifestation
by frequency in our cohort (43.6%), while it has a high
variability in the other populations, from 8.7% in UK to
81% in Turkey [16], even if the latter finding come from
a study performed in an Ophthalmology Department.
Skin involvement rate in our patients was similar to
those from UK and much lower than those from all
other countries. Vascular manifestations were seen with
Fig. 2 Frequency of clinical features
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the highest frequency in Tunisia (32.1%) [15], much
higher when compared to our series (1.8%). Vascular
involvement has a wide range (5-40%) in the literature
and this could be due to the difference between
reference centers, patients with different disease
duration and ethnic variations, being quite rare in the
Far-East [18]. In our cohort, the percentage of neuro-
logical involvement was 30.9% similar to the study by
Kone-Paut [19] and Brogan [14]; other studies had a sig-
nificantly lower involvement rate. These differences may
be due to the fact that in countries with a higher per-
centage of neurological involvement, isolated headaches
were considered a neurologic symptom, although it is
not included among the criteria for the diagnosis of
Neuro-Behçet. In our study, isolated headaches were
present in 24.5% of cases. In the PEDBD study [12], the
presence of headaches was significantly associated with
BD confirmation by experts (p = 0.0063). Joint involve-
ment was reported with a percentage of about 40% in all
studies evaluated, including ours, but was lower in a
Turkish study [20] and in one from Korea [21]. GI
involvement was frequent in our series and in UK cohort
with a rate of 42-58%, much lower in all other studies
(4.8-14%) [19, 21–23]. Arthralgia (24.5%) and abdominal
pain (22.7%) without any organic involvement were very
frequent in our population. Pathergy phenomenon was
known to be present mostly in Turkey, Tunisia and Iran
[15, 16, 22] (49.4-63.2%); in our Caucasian series it was
14.5%. This data cannot be compared to the other
Caucasian population in UK, since it was performed in
only 5 out of 46 patients. We also assessed constitutional
symptoms and recorded a rate of 28% of fatigue and
malaise, while 6.4% patients complained of mood disor-
ders. Thirty-four patients had recurrent fever with
irregular pattern.
We have assessed the correlations between clinical
findings and gender without finding statistically signifi-
cant data, even if we have found a greater frequency of
skin, ocular and vascular manifestations in males and
GU in females. We also assessed all the clinical findings
and disease onset age and discovered that patients with
neurological involvement had a higher average age of
BD onset than those who did not (p = 0.002). We also
recorded similar data for vascular involvement, though
not statistically significant (p = 0.071). This kind of cor-
relation has not been assessed in the other studies. The
presence of HLA B51 was (56.8%) similar to Tunisia and
its presence was higher in patients with ocular involve-
ment (p = 0.219). Our results overall are very similar to
the UK study and differ from other studies coming from
Silk Road, highlighting a key role of racial differences
and/or environmental factors.
We employed ISG, ICBD and, for the first time,
PEDBD criteria with our patients and demonstrated a
sensitivity of 29.1% with ISG, 70.9% ICBD and 45.5%
PEDBD. These data confirm the limits of ISG, the
greater sensitivity of ICBD and PEDBD, albeit lower in
the latter case. A limit of ISG is ROA as a mandatory























Total number of PEDBD
patients
110 1973 110 83 86 62 81 40 46
Male/female ratio 1.3 1.0 0.6 0.8 1.0 1.1 2.1:1 0.67 0.9
Average age at onset 8.3 n.r. 11.6 ± 3.4 12.3 8.4 n.r. 16.12 ± 3.7 n.r. 4.87
ROA 94.5a 97.8 100 100 97.2 100 100 100 97.8
GU 33.6 64.7 82.7 82 60.4 55 76.5 82.5 74
Skin manifestations 39.6 65.3 76 n.r. 93 n.r. 88.9 72.5 32.6
Ocular involvement 43.6 56.1 30.9 35 57 n.r. 44.4 27.5 8.7
Vascular manifestations 1.8 6.5 3.6 9.6 16.2 5 32.1 n.r. 6.5
Joint involvement 42.7 37.1 22.7 40 45.3 42 40.7 27.5 52
CNS 30.9 10.3 3.6 7.2 36 13 22.2 2.5 32.6
GI lesions 42.7 7.6 n.r. 4.8 14 n.r. n.r. 5 58.7
Pathergy phenomenon 14.51 49.4 45.5 37 63.22 47 55.7 17.5 603
Relatives affected 124 n.r. 12.3 19 16.2 42 n.r. 22.5 17
ROA Recurrent oral aphtosis, GU Genital ulcers, CNS central nervous system, GI Gastrointestinal, nr not reported
aall clinical manifestations are expressed in percentage
1Pathergy test was performed in 103/110 patients and was positive in 15/103
2Pathergy test was performed in 68/86 patients and was positive in 43/86
3Pathergy test was performed in 5 patients and was positive in 3/5
4Data not known in 10 patients; 12/110 patients had a positive family history
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criterion and the absence of neurological and vascular
involvement; on the contrary, ICBD have no mandatory
criteria and neurological and vascular manifestations
have been added, as well as in PEDBD. The last two cri-
teria give a different weight to every item: 2 points for
ROA, GU and ocular lesions and 1 point for all the
others in ICDB and 1 point for each one in PEDBD. This
means that only two items are needed to diagnose BD
with ICBD, but 3 items with PEDBD. Among our 110
patients, 31 (28%) were defined by the experienced cen-
ters as suspected or probable BD even if they did not
fulfill any of the three criteria used: 18 had only ROA, 7
ROA and skin lesions, 5 only ocular manifestations and
1 had only skin lesions. In most of them, the positive
family history, the presence of a chronic or recurrent
systemic inflammation, the presence of HLA-B51 and
the response to treatment (mainly colchicine) was the
main reason to include them in the registry. Notably, in
most of these patients the administration of a continu-
ous treatment clearly influenced the natural clinical
course of the disease. It is therefore difficult to clearly
determine if these patients would have the chance to
develop other BD-related clinical manifestations in their
follow-up. A longitudinal study, already planned, will
provide evidence of the proportion of these patients that
will reach a definitive diagnosis. In any case, our cohort
identifies the existence of a sort of “gray-zone” of
pediatric patients that do not fulfill any of the clinical
criteria for BD, but must be treated with the same thera-
peutic approaches used in patients that fulfill at least
one of the ongoing diagnostic/classification criteria.
BD enters in differential diagnosis with autoinflamma-
tory diseases (AID), so we assessed constitutional symp-
toms in our cohort and recorded recurrent fever in one
third of our population (34 patients): 16 of them have
also been studied for the most common AID (FMF,
TRAPS, HIDS) without finding any mutations. In a
PEDBD cohort of Kone-Paut, 44% of children had recur-
rent fever, a sign mostly associated to vascular and
neurological disease, but also observed in association
with attacks of ROA, which may seem to be Periodic
Fever Aphtosis Pharyngitis and Adenitis (PFAPA)
syndrome [9].
In BD, there is no approved treatment guideline and a
specific therapy based on organ involvement on a case-
by-case basis is usually carried out. All our patients re-
ceived topical steroid therapy (ocular and/or mucocuta-
neous). The systemic treatments more commonly used
were colchicine and corticosteroids, followed by immu-
nosuppressants. All patients who took colchicine as
monotherapy, presented a clinical picture characterized
by ROA, frequently associated with GU and skin lesions.
Patients who received immunosuppressive therapy with
or without colchicine had all severe ROA, to a lesser
degree GU, but many of them had ocular involvement.
Four patients received biologic therapy: 2 of them anti
TNF-α (Infliximab) and 2 anti IL-1 (Anakinra), for
severe ocular, neurological, GI and mucocutaneous
involvement. Among the populations we evaluated, only
UK study used anti TNF-α agents. Some pediatric case
reports and case series described the efficacy and safety
of TNF-α inhibitors to manage many BD manifestations;
more recently IL-1 blockade have been successfully used
to treat severe BD cases and/or refractory to anti TNF-α
[24–27]. Many of our patients received drug combina-
tions and twenty of them needed to change two, three
or even four medication types.
Conclusion
We described the baseline data of the first national epi-
demiological study on pediatric BD in Italy. We noted a
high frequency of familial cases, confirming a strong
genetic influence. ROA is by far the most frequent clin-
ical manifestation, followed by ocular involvement; GI
lesions are more frequent in Italy than in non-European
countries as opposed to GU. We also recorded a higher
frequency of skin, ocular and vascular manifestations in
males and GU in females. Constitutional symptoms,
rarely mentioned before, worsen definitely quality of life.
Recurrent fever was present in one third of our popula-
tion. Our data confirm a better sensitivity of ICBD and
PEDBD in children when compared to ISG criteria.
Colchicine and corticosteroids were the main treatments
and some severe cases received biologic agents (anti
TNF-α and anti-IL-1). The study suffers for the lack of
longitudinal data. Thus the results refer only on the clin-
ical manifestations and treatments from disease onset to
the enrollment in the national cohort. Longitudinal data
will provide precious information on the evolution of
the disease and on the efficacy and safety of different
treatments used in this condition.
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